What an Injectable GLP-1 Costs a Month

The sample is every recorded offer that met five conditions at once on the day it was read: it is billed on a monthly cadence, it carries a verified recurring charge, its medication and formulation are identified, it has a dated source page, and its commitment wording establishes that one period can be stopped. Oral products are removed by form, not by assumption about the molecule.

324 recorded offers were assessed. 45 met every rule and form the sample. The rest were excluded for the reasons below, and each exclusion is a recorded fact about that offer rather than an editorial opinion.

Microdose-specific plan, excluded by standing rule

2

Record held for reconciliation, not a current offer

6

Oral formulation, published in its own separate view

24

Prepaid package, one-time purchase, or no monthly billing cadence

173

A required fee is recorded but not quantified

2

Introductory, trial, first-period or promotional amount

17

Restricted-group, coupon or prepaid amount

4

No dated source page

8

Commitment wording does not establish a one-period exit

41

Eligible monthly plan with no readable injectable price

2

A microdose-specific plan is never published on this site, at any price, and an advertised-only listing or a sponsored placement never enters the record layer at all, so neither can reach this sample. Both exclusions are stated here rather than assumed.

The median is the midpoint of the recorded prices. It is used instead of an average because a single brand-name plan at $1,828 would drag an average upward and describe no plan a reader can actually buy.

One check on the arithmetic. Counting each program once, at its own lowest recorded monthly price for that molecule, moves the tirzepatide median from $285 to $299, because 6 of the tirzepatide rows are dose tiers published by 1 program. Each tier is a real price a buyer meets, so both figures are reported instead of picking one. Semaglutide is unchanged at $214 on the same basis, because its rows are one plan per program.

A median hides both ends. These are the actual cheapest and dearest recorded plans in each molecule, named, because a range without names cannot be checked.

Tirzepatide low

$199 a month, Renlo Health.

Tirzepatide high

$1,828 a month, Fridays.

Semaglutide low

$149 a month, Idgie Health.

Semaglutide high

$1,498 a month, Fridays.

No annual or twelve-month figure is published anywhere in this study. A four-week cycle is charged about thirteen times a year and a calendar month twelve, so a single yearly number would compare two different spans of coverage as if they were the same. Every figure here is one monthly charge.

The absence of a recorded separate membership fee does not establish that every plan is all-inclusive. Some records leave membership amounts or conditional charges open. See ‘Where the price stops being complete’ before treating a recorded charge as a complete total.

6 plans do not establish whether a separate membership amount exists at all. An unpublished amount is neither zero nor a charge, so it is reported as open here rather than counted as a fee or as a saving.

This is a fact about the sample, not a claim about the market. A program that bills a membership beside a separately priced drug often cannot produce one verified combined monthly figure, so it fails the inclusion rule and sits in the exclusion ledger instead. That is why a reader who goes looking for membership-billed programs will not find them in these 45 rows.

A flat price is a claim that the charge does not step up as the dose rises. 28 plans record one flat price across the doses they list, and 3 record a dose-based ladder. The remaining 14 do not state a dose basis in the record.

A flat advertised price is not the same as a verified flat total. Several of these plans still leave the supported dose range or the exact supply a charge covers unstated, and those gaps stay visible on each program's own profile rather than being smoothed into the headline number. The guide's own program is one of the recorded rows and is treated exactly like every other row.

20 of 45 plans publish a cost scope that stops short of an all-in promise, naming conditional or separately billed charges where any apply. Their recorded figure is a standard plan charge, not a ceiling. 0 plans carry a required fee the provider does not quantify.

Counting both measures together, 20 plans leave at least one part of the total price open: every plan with an unpublished membership amount also stops short of an all-in promise, so the two sets overlap rather than adding up. Every one of those plans is still in the sample, because each has a verified monthly charge for the plan itself. The open portion is disclosed rather than silently treated as zero, which is the distinction this page exists to make: a recorded price is not the same claim as a complete price.

Each row was read from the provider's own pricing, checkout or terms page and dated to the day it was read. Provider pages read October 15, 2026 to November 10, 2026, across 7 distinct dates. A figure therefore carries its own date rather than a single freshness stamp for the page.

Measured amounts include verified mandatory recurring fees recorded against each offer; unverified or conditional costs are not treated as zero. A one-time fee is never divided into a monthly figure and never summed into one; where a plan carries one it is printed as its own labelled line on that program's profile. Nothing was converted from another billing interval, and no average monthly equivalent was substituted for a charge the provider actually takes.

Statistics are computed from the published rows themselves rather than typed in, so the medians, quartiles and counts on this page move automatically when a record moves. The field dictionary behind every recorded row is on program cost research, the raw rows with their source URLs are on the open dataset, and the sourcing rule itself is on how we compare. No earlier page on this site computed a median, a quartile or a price range across the recorded rows; this is the first.

The 21 programs here are a chosen set, not a census of the US market. A median over a selection describes that selection, and no figure on this page should be read as the market average price.

Prices move. A figure is accurate to its check date and no further, and a re-read can change it. The two brand-name rows are recorded cash prices for FDA-approved products, which is a different purchase from a compounded preparation, and the tables label which is which rather than pooling them silently.

Nothing here is a clinical claim, a recommendation, or a statement that two products are equivalent. It is a price and terms measurement.